"10.1371_journal.pone.0047578","plos one","2012-11-30T00:00:00Z","Lars Börnsen; Jeppe Romme Christensen; Rikke Ratzer; Annette Bang Oturai; Per Soelberg Sørensen; Helle Bach Søndergaard; Finn Sellebjerg","Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark","Conceived and designed the experiments: LB JRC HBS FS ABO. Performed the experiments: LB JRC HBS RR. Analyzed the data: LB JRC FS HBS FS. Contributed reagents/materials/analysis tools: FS HBS PSS ABO. Wrote the paper: LB.","The authors have read the journals policy and report the following conflicts: Lars Börnsen reports no disclosures. Jeppe Romme Christensen has received honoraria for lecturing from Biogen-Idec. Rikke Ratzer reports no disclosures. Helle B. Søndergaard reports no disclosures. Annette Bang Oturai has served on scientific advisory boards for Novartis, has received speaker honoraria from Biogen Idec, Merck Serono, and Novartis; and has received research support from the Danish Multiple Sclerosis Society, the Warwara Larsen Foundation and the Johnsen Foundation. Per Soelberg Sorensen has served on scientific advisory boards for and received funding of travel for these activities from Biogen Idec, Merck Serono, Novartis, Genmab, TEVA, Elan; has served as Editor-in-Chief of the European Journal of Neurology, and as an editorial board member for Therapeutic Advances in Neurological Disorders and Multiple Sclerosis; receives speaker honoraria from Biogen Idec, Merck Serono, TEVA, Bayer Schering, Sanofi-aventis, and Novartis; and has received research support from Biogen Idec, Bayer Schering, Merck Serono, TEVA, Baxter, Sanofi-Aventis, BioMS, Novartis, Bayer, RoFAR, Roche, Genzyme, and from the Danish Multiple Sclerosis Society, the Danish Medical Research Council, and the European Union Sixth Framework Programme: Life sciences, Genomics and Biotechnology for Health. Finn Sellebjerg has served on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva; has received funding for travel from Sanofi-Aventis and Teva; has served as a consultant for Novo Nordisk; has received speaker honoraria from Bayer-Schering, Biogen Idec, Merck-Serono, Sanofi-Aventis, Schering-Ploug; and has received research support from Biogen Idec and Sanofi-Aventis, from the Danish Medical Research Council (#271-06-0246), the Danish Strategic Research Council (#2142-08-0039); the Lounkær Foundation, the Danish MS Society, the Johnsen Foundation, and the Warwara Larsen Foundation. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","11","Lars Börnsen","LB",7,TRUE,5,4,4,1,TRUE,TRUE,FALSE,0,NA,FALSE
